Open AccessTET2 mutations in secondary acute myeloid leukemias: a French retrospective study
Author(s) -
Olivier Kosmider,
Éric Delabesse,
Véronique MansatDe Mas,
Pascale CornilletLefèbvre,
Odile Blanchet,
Alain Delmer,
Christian Récher,
Stéphane Raynaud,
Didier Bouscary,
F Viguié,
Catherine Lacombe,
O. Bernard,
Norbert Ifrah,
François Dreyfus,
Michaëla Fontenay
Publication year - 2011
Publication title -
haematologica
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2011.040840
Subject(s) - myeloid leukemia , medicine , myeloid , chromosomal translocation , retrospective cohort study , karyotype , mutation , hematology , leukemia , oncology , immunology , gastroenterology , cancer research , gene , biology , genetics , chromosome
Ten-eleven translocation 2 (TET2) mutations have been involved in myeloid malignancies. This retrospective study aims at evaluating the frequency and impact of TET2 mutations in 247 secondary acute myeloid leukemia cases referred to as myelodysplasia-related changes (n=201) or therapy-related (n=46) leukemias. Mutation of at least one copy of the TET2 gene was detected in 49 of 247 (19.8%) patients who presented with older age, higher hemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. TET2 mutations were significantly less frequent in therapy-related (8.7%) than myelodysplasia-related changes (22.3%; P=0.035) leukemias and strongly associated with normal karyotype (P<0.001). TET2 mutations did not significantly associate with NPM1, FLT3-ITD or FLT3-D835, WT1, or N- or K-RAS mutations. Complete remission was achieved in 57% of evaluable patients who had received intensive chemotherapy. In this group, TET2 mutations did not influence the complete remission rate or overall survival.